Hayadan > compugen

compugen

Immune Control Protein Discovered by Compugen Shows Potential for Developing New Cancer Immunotherapy Drugs

The science service
November 14, 2016
No comments

Biotechnology - group of announcements: Compugen, Glamed and Itamar Medical, Algatech

The science service
October 4, 2014
One response

Biotechnology cluster: Levitas Cardio recruits; And also on: Protlix, Yes Fit, Redhill Biopharma, Compugen and a joint venture with Germany in the field of biotechnology

The science service
October 21, 2013
No comments

Biotechnology Cluster: New Incubator Company; European marketing agreement for Silantis seal; Co-op Compugen-Bayer

The science service
August 14, 2013
No comments

Compugen and Mark Sarono's venture capital fund are jointly establishing Neviah Genomics) a new company for the discovery and development of diagnostic markers

The science service
June 28, 2012
No comments

Compugen expands and accelerates the program to develop antibodies to treat cancer and diseases of the immune system

The science service
December 24, 2011
No comments

The hunger for knowledge

Weizmann Institute
March 19, 2010
One response

Compugen Announces New Platform for Identifying Viral Peptides for Drug Use Against Human Inflammatory Diseases

The science service
October 26, 2008
No comments

Compugen announces the discovery of a new medicinal peptide candidate for the treatment of solid cancerous tumors

The science service
September 24, 2008
No comments

Compugen announces discovery of markers for early detection of kidney damage caused by drugs in preclinical development stages

The science service
June 26, 2008
No comments

Compugen Announces Discovery of New Targets for Drug Antibodies for Cancer

The science service
June 13, 2008
No comments

Compugen reports finding a marker to detect the destruction of heart tissue

The science service
April 2, 2008
No comments

Compugen announces a new platform for the discovery of peptides that block protein structures associated with diseases

The science service
March 19, 2008
2 תגובות

Compugen announces an agreement with Teva covering a protein variant of MCP1 for the treatment of chronic inflammatory diseases

The science service
September 11, 2007
One response

Clal Biotechnology Industries has announced that it has completed the acquisition of DiaPep277 rights from Davlogan

Avi Blizovsky
June 17, 2007
No comments

Compugen to Collaborate with Mayo Clinic to Discover New Diagnostic Markers for Unstable Atherosclerotic Plaque

The science service
May 1, 2007
No comments

Compugen: cooperation for the development of diagnostic products with Johnson & Johnson

Avi Blizovsky
June 9, 2005
No comments

Compugen and Novartis will collaborate on research in the field of systems biology

Avi Blizovsky
April 20, 2005
No comments

Ivogen and Compugen will test the production of human proteins in wild tomatoes

Avi Blizovsky
October 26, 2004
No comments

Compugen announces a scientific breakthrough: a fifth nucleic acid in RNA is more common than known

The science service
July 19, 2004
No comments

Compugen establishes Kedem Biosciences, a subsidiary for the discovery of small molecules for pharmaceutical purposes

Avi Blizovsky
July 2, 2004
No comments

Compugen and Tel Aviv University discovered a unique prediction method

Avi Blizovsky
January 28, 2004
No comments

Compugen enters the DNA chip manufacturing market; Celera offered the Israeli government to buy the use of

Avi Blizovsky
December 1, 2000
No comments

Who owns the rights to the human genome?

The science service
July 1, 2000
No comments

The book is already here, you just have to learn to read - an interview with one of the heads of the human genome project

The science service
June 16, 2000
No comments